# Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

> **NCT00777530** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer
- Tumors
- Leukemia

## Interventions

- **DRUG:** Bosutinib (SKI-606)

## Key facts

- **NCT ID:** NCT00777530
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2008-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777530, "Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00777530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*